Myriad Gene Patent Fight: Biotech And Pharma Are Ringside For Round Two
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry wants a narrow decision as the Biotechnology Industry Organization urges the Federal Circuit to protect composition of matter claims in reconsidering the ACLU’s suit against Myriad; Lilly calls for the court to create a bright patent-eligibility line.
You may also be interested in...
Myriad Gene Patent Case May Go To Supreme Court After Federal Circuit Backs Firm
A Federal Circuit panel again rules that Myriad Genetics’ patents covering BRCA genes isolated from the body are patent-eligible; the ACLU may request review by the full court or file a petition with the Supreme Court.
Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm
The court’s finding that Prometheus’ drug calibration test is unpatentable has left the biotech community reeling with uncertainty as to whether method of treatment claims, particularly those involving biomarkers, will be patent eligible.
Myriad's BRCA Gene Patents Struck Down In Court; Are Biotech's Foundations Shaking?
Judge finds that isolated DNA is not different from that in the body and thus unpatentable; Myriad says its products are covered by other patents.